Physician profile
Mark E Stevens
NPI 1891732897
$2,392.00
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $438 · 2021: $421 · 2022: $323 · 2023: $434 · 2024: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $321.86 | 2019-2024 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $310.73 | 2019-2021 | |
| Pfizer INC. | $210.77 | 2019-2024 | |
| Novo Nordisk INC | $199.29 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $198.34 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $166.14 | 2019-2024 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.33 | 2019-2020 | |
| Amgen INC. | $93.68 | 2019-2024 | Repatha, Otezla |
| Inspire Medical Systems, INC. | $82.62 | 2023 | Inspire |
| Novartis Pharmaceuticals Corporation | $80.23 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $68.34 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $64.86 | 2019-2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $58.29 | 2020-2021 | |
| Eisai INC. | $37.79 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.34 | 2020-2023 | Xifaxan, Trulance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.17 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $33.26 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.39 | 2022 | |
| Amarin Pharma, INC. | $28.34 | 2019-2022 | |
| Abbott Laboratories | $24.87 | 2021 | |
| Axsome Therapeutics, INC. | $23.05 | 2024 | Auvelity |
| Allergan, INC. | $21.07 | 2020 | |
| Melinta Therapeutics, LLC | $17.72 | 2019 | |
| Daiichi Sankyo INC. | $17.04 | 2020 | |
| Radius Health, INC. | $16.54 | 2019 | |
| Genentech USA, INC. | $14.21 | 2019 | |
| Biogen, INC. | $14.08 | 2021 | |
| Lilly USA, LLC | $13.98 | 2022 | |
| Esperion Therapeutics, INC. | $13.82 | 2021 | |
| Ibsa Pharma INC. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.